Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.
Read More »
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Nov 13, 2017|
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
|Nov 7, 2017|
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update
|Oct 25, 2017|
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYS™ (KPI-121 1%)
|There are currently no events scheduled.|